Bipolar Disorder Treatment Market

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent the triggering of maniac episodes in patients with bipolar disorder. There is a sudden change in the mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. People suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns, and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient’s symptoms, family history, and life history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market is expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

• This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bipolar disorder treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global infection surveillance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

• Global Bipolar Disorder Treatment Market, By Drug Class:
  • Antipsychotics
  • Antidepressants
  • Mood Stabilizers
  • Anti-anxiety Drugs and Others
• Global Bipolar Disorder Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Bipolar Disorder Treatment Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Takeda Pharmaceutical Company Limited*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer, Inc.
  • Allergan plc
  • Otsuka Holdings Co. Ltd.
  • Johnson & Johnson
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • AstraZeneca Plc
  • Novartis International AG
  • AbbVie Inc.
  • Lundbeck A/S
  • Minerva Neurosciences
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Intra-Cellular Therapies Inc.
  • Gedeon Richter Plc.
  • Indivior PLC

 “*” marked represents similar segmentation in other categories in the respective section.